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ABSTRACT
Background: Biomarkers may facilitate clinical decisions in order to guide antimicrobial treatment and
prediction of prognosis in community-acquired pneumonia (CAP). We measured serum C-reactive
protein, procalcitonin (PCT) and calprotectin levels, and plasma pentraxin 3 (PTX3) and presepsin levels,
along with whole-blood white cell counts, at three time-points, and examined their association with
microbial aetiology and adverse clinical outcomes in CAP.
Methods: Blood samples were obtained at hospital admission, clinical stabilisation and 6-week follow-up
from 267 hospitalised adults with CAP. Adverse short-term outcome was defined as intensive care unit
admission and 30-day mortality. Long-term outcome was evaluated as 5-year all-cause mortality.
Results: Peak levels of all biomarkers were seen at hospital admission. Increased admission levels of C-
reactive protein, PCT and calprotectin were associated with bacterial aetiology of CAP, while increased
admission levels of PCT, PTX3 and presepsin were associated with adverse short-term outcome. In
univariate and multivariate regression models, white blood cells and calprotectin at 6-week follow-up were
predictors of 5-year all-cause mortality.
Conclusions: Calprotectin emerges as both a potential early marker of bacterial aetiology and a predictor
for 5-year all-cause mortality in CAP, whereas PCT, PTX3 and presepsin may predict short-term outcome.
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Community-acquired pneumonia (CAP) remains a frequent infectious condition, responsible for
considerable short- and long-term morbidity and mortality [1]. Despite preventive measures, the burden
of this disease is expected to increase in the coming years [2]. For optimal management and use of
healthcare resources in CAP, early identification of the causative agent(s), recognition of disease severity
and prediction of unfavourable outcome is of major importance. Biomarkers, applied in synergy with
clinical assessment and CAP-specific severity scores, may provide additional information on disease
severity and on the distinction between bacterial and viral aetiology. At present, however, biomarkers that
discriminate viral infections from bacterial and mixed viral–bacterial causes of CAP are not precise enough
to allow pathogen-specific therapy [3], nor have biomarkers provided a definite advantage over
CAP-specific severity scores for predicting poor short- and long-term prognosis [4, 5]. Thus, new
noninvasive diagnostic and prognostic tools could benefit the assessment and management of CAP, to
better guide therapeutic options, avoid antibiotic overuse and improve clinical short-term outcomes [6].
Biomarkers could also identify patients at risk of poor long-term outcomes, defining a subgroup of CAP
survivors that should be followed more carefully.
White blood cell (WBC) count and the short pentraxin C-reactive protein (CRP) are widely available
inflammatory biomarkers of low to intermediate value for prediction of microbial patterns and disease
severity in CAP [7–9]. The calcitonin precursor procalcitonin (PCT) is assumed to be a superior marker of
bacterial aetiology and outcome in CAP compared with the former two [4, 7, 10], in addition to being
useful for guiding the duration of antibiotic treatment in CAP [11]. In comparison, soluble CD14 (sCD14)
subtype, known more simply as presepsin, is a molecule suggested to be more specific to systemic
infections than WBCs, CRP and PCT, potentially serving as a predictor of severe disease and short-term
mortality in CAP [12, 13]. More recently, the neutrophil-associated biomarker calprotectin and the long
pentraxin 3 (PTX3), reflecting local and not systemic inflammation, have emerged as promising
acute-phase markers of systemic infections [14, 15], but the utility of these markers in CAP is less clear
[16, 17].
We have previously reported a high diagnostic microbial yield in a well-defined cohort of 267 hospitalised
adult patients with CAP [18]. In this study, our objective was to quantify levels of WBCs, CRP and PCT,
as established inflammatory biomarkers, along with calprotectin, PTX3 and presepsin, at three study
time-points, and examine the association between these biomarkers and microbial aetiology, and short-
and long-term outcome in CAP.
Materials and methods
Study population and design
The study was performed in an acute-care, 270-bed general hospital in Drammen, Vestre Viken Hospital
Trust, in south-eastern Norway between January 1, 2008, and January 31, 2011. A total of 267 patients aged
⩾18 years admitted with suspected pneumonia to the Dept of Internal Medicine were consecutively recruited.
Within the first 48 h of hospital admission, patients were screened for eligibility by determining the presence
of CAP criteria, defined by 1) a new pulmonary infiltrate on chest radiography, 2) rectal temperature >38.0°C
and 3) at least one of the following symptoms or signs: cough (productive or nonproductive), dyspnoea,
respiratory chest pain, crackles or reduced respiratory sounds. Patients were excluded from the study if they
had been hospitalised within the past 2 weeks or if the chest radiograph uncovered noninfectious findings.
Immunocompromised patients (i.e. primary or acquired immunodeficiency, active malignancy, and patients
using immunosuppressive drugs, as defined by HOLTER et al. [19]) were not excluded from the study in order
to reflect the total population being referred to this local hospital. The inclusion process is presented in figure
S1. Patients were invited to an outpatient follow-up ∼6 weeks after hospital discharge, i.e. during the
convalescent phase of CAP. All patients provided written informed consent. The study was approved by the
Regional Committee for Medical and Health Research Ethics in South-Eastern Norway (ref. number
S-06266a) and a waiver of consent was obtained from the committee to link patient data to death certificates
(2012/467 A).
Data collection and definitions
Baseline data collection and definitions have been described elsewhere [18, 19]. In short, demographic,
clinical and laboratory data were collected within 48 h of admission, mean±SD time from hospital
admission to study inclusion was 0.6±0.5 days and 260 of 267 (97%) patients were included within 24 h.
The microbial aetiology of CAP was established by use of a comprehensive array of microbiological tests
(i.e. bacterial cultures, serology, urinary antigen assays and PCR). In the present study, clinical stabilisation
was evaluated daily during the first 12 days of hospitalisation, with CRP and WBCs measured every
second day, according to the following criteria (1 point for each criterion): 1) unchanged antibiotic
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treatment the last 2 days, 2) improvement of general condition, 3) morning rectal temperature <38.0°C
and 4) >25% decrease in CRP or WBC levels. Clinical stabilisation was defined as a score of ⩾3 points.
Blood sampling
Blood samples were obtained at hospital admission, clinical stabilisation and at the 6-week follow-up, with
serum and plasma samples drawn into pyrogen-free vacutainer tubes. Tubes for plasma samples contained
EDTA as an anticoagulant. Serum or plasma was separated from whole blood within 60 min by
refrigerated centrifugation at 2000g for 12 min and stored in several aliquots at −80°C.
Biomarker analysis
Serum CRP was measured by turbidimetry (Abbott Architect ci16200; Abbott Diagnostics, Abbott Park,
IL, USA), while full-blood WBCs with automated differential count were counted on a CELL-DYN 4000
haematology analyser (Abbott Diagnostics) and an Advia 120 Hematology System (Siemens Healthineers,
Erlangen, Germany). Serum PCT was measured using a chemiluminescent assay (Advia Centaur
BRAHMS PCT; Siemens Healthineers). Serum calprotectin was analysed with an ELISA (Calpro AS, Oslo,
Norway) on an automated ELISA instrument (Dynex DS2 Automated ELISA System; Dynex Technologies
Inc., Chantilly, VA, USA). Both plasma PTX3 and presepsin levels were analysed by commercially
available sandwich ELISAs (R&D Systems, Minneapolis, MN, USA, and MyBioSource Inc., San Diego, CA,
USA, respectively).
Outcome measures
Based on the microbiological results, four aetiological groups were analysed: 1) bacterial, 2) viral, 3)
viral–bacterial and 4) unknown. Disease severity was evaluated by the validated CURB-65 severity score
(confusion, urea >7 mmol·L−1, respiratory rate ⩾30 breaths·min−1, blood pressure <90 mmHg (systolic) or
⩽60 mmHg (diastolic), age ⩾65 years); patients with a CURB-65 score of ⩽2 were classified into low-risk
and ⩾3 into high-risk groups [20]. Short-term outcome was defined as a composite endpoint of intensive
care unit (ICU) admission and 30-day mortality. Long-term outcome was evaluated as 5-year all-cause
mortality.
Statistical analysis
Categorical variables are presented as n (%). Continuous variables are presented as mean±SD for normally
distributed data or median (interquartile range) for skewed data. Differences in biomarker levels between
aetiologies and time points were analysed with Kruskal–Wallis and Friedman tests for multiple-group
comparisons, and Mann–Whitney and Wilcoxon signed-rank tests for two-group comparisons. Correlation
analysis between continuous variables was performed with Spearman’s rank-order correlation. Univariate
and multivariate logistic regression analysis examined the association between biomarkers and bacterial
aetiology or short-term outcome. The diagnostic accuracy of biomarkers for predicting bacterial aetiology
or short-term outcome was calculated by area under the curve (AUC). In dichotomous analysis, bacterial
aetiology was defined as pure bacterial or mixed viral–bacterial CAP. Cut-off values were determined by
use of the Youden index. Survival from 30 days until death or the end of the follow-up period was
described for all survivors using Kaplan–Meier plots. Survival distributions were compared with the
log-rank test. Univariate and multivariate Cox regression analysis examined the association between
biomarkers and long-term outcome. Continuous variables were log-transformed before inclusion in
regression analysis if skewed. A two-sided p-value <0.05 was considered to be significant. Statistical
analyses were performed using STATA version 15.0 for Windows (Stata Corp LP, College Station, TX,
USA) and SPSS version 25.0 for Windows (IBM Corp, Armonk, NY, USA).
Results
Baseline characteristics
Baseline characteristics of the study cohort have previously been reported [18] and are briefly summarised
in table S1. Median age was 66 (52–78) years and 172 (64%) patients had at least one comorbid condition.
Microbial aetiology was established in 167 (63%) patients; 73 (28%) patients had a bacterial infection, 41
(15%) a viral infection and 51 (19%) a viral–bacterial infection, while 100 (37%) had CAP of unknown
aetiology (table 1).
Biomarker levels at study time points
Peak levels of all examined biomarkers were seen at hospital admission, with significantly lower levels seen
at clinical stabilisation during hospitalisation (p<0.001 for all) and at the 6-week follow-up (p<0.001 for
all) (figure 1). Neutrophil granulocytes correlated strongly with WBCs at all three time points (correlation
coefficient r=0.982, r=0.953 and r=0.937 at time points 1–3, respectively; p<0.001 for all).
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Biomarker levels at hospital admission in relation to microbial aetiology
The distributions of the biomarkers WBC, PTX3 and presepsin were similar at hospital admission in
relation to microbial aetiology (figure 2a–c). For CRP and PCT, however, admission levels were
significantly higher in bacterial and viral–bacterial CAP compared with viral CAP (figure 2d and e), while
calprotectin levels were higher in viral–bacterial CAP compared with viral CAP (figure 2f).
In logistic regression analysis of continuous variables, increased admission levels of CRP (OR 1.90, 95% CI
1.16–3.12; p=0.011), PCT (OR 1.44, 95% CI 1.15–1.81; p=0.002) and calprotectin (OR 2.15, 95% CI
1.05–4.45; p=0.036) were significantly associated with bacterial aetiology of CAP (table 2). The diagnostic
accuracy for discriminating bacterial infections from viral infections of CAP was, however, of moderate
value for these three markers (table 2). The optimal cut-off value for discriminating bacterial infections
from viral infections for CRP was 176 mg·L−1 (sensitivity 72%, specificity 51%), for PCT was 0.45 ng·mL−1
(sensitivity 70%, specificity 65%) and for calprotectin was 3476 µg·L−1 (sensitivity 73%, specificity 50%).
TABLE 1 Microbial findings in 267 hospitalised patients with community-acquired pneumonia
Bacterial pathogens Patients with positive findings Viral pathogens Patients with positive findings
Streptococcus pneumoniae 81 (30%) Influenza viruses§ 40 (15%)
Bordetella pertussis 15 (6%) Rhinovirus 32 (12%)
Haemophilus influenzae 14 (5%) Parainfluenza virusesƒ 8 (3%)
Mycoplasma pneumoniae 10 (4%) Respiratory syncytial virus 7 (3%)
Chlamydophila pneumoniae 7 (3%) Metapneumovirus 7 (3%)
Legionella pneumophila 7 (3%) Enterovirus 5 (2%)
Enterobacteriaceae# 6 (2%) Adenovirus 1 (0.4%)
Moraxella catarrhalis 5 (2%)
Miscellaneous¶ 3 (1%)
Haemophilus parainfluenzae 2 (1%)
Total+ 126 (47%) Total+ 92 (34%)
#: Escherichia coli, Pseudomonas aeruginosa or Enterobacter spp.; ¶: group A Streptococcus, Prevotella spp. or Dialister pneumosintes; +: number
of patients does not sum to number of pathogens because some patients had multiple pathogens detected; §: influenza A and B viruses;

































































































































































FIGURE 1 Biomarker levels at hospital admission, clinical stabilisation and 6-week follow-up in 267 hospitalised patients with
community-acquired pneumonia. a) White blood cells; b) C-reactive protein; c) procalcitonin; d) calprotectin; e) pentraxin 3; f ) presepsin.
*: p<0.05; **: p<0.01; ***: p<0.001. Two-group comparison performed with Wilcoxon signed-rank test.
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When comparing biomarkers at admission between encapsulated bacteria (e.g. Streptococcus pneumoniae
or Haemophilus influenzae) and atypical bacterial infections (e.g. Mycoplasma pneumoniae, Bordetella
pertussis, Chlamydophila pneumoniae or Legionella pneumophila), patients with CAP caused by
encapsulated bacteria had significantly higher levels of PCT (p=0.049) and WBCs (p=0.003). No
significant differences in biomarker levels were seen for CRP, calprotectin, PTX3 or presepsin (p=0.379,
p=0.449, p=0.281 and p=0.063, respectively).
Biomarker levels at hospital admission in relation to short-term outcome
A total of 51 (19%) patients were admitted to the ICU (n=48, 18%) and/or died within 30 days of
admission (n=10, 4%). Compared with the remaining study cohort, patients with an adverse short-term
outcome had higher admission levels of PCT, PTX3 and presepsin, but not of CRP, WBCs or calprotectin
20 p=0.166

































































































































































FIGURE 2 Biomarker levels at hospital admission stratified by microbial aetiology in 267 hospitalised patients with community-acquired
pneumonia. Data are presented as medians with interquartile ranges. Multiple group comparison performed with Kruskal–Wallis test and
two-group comparison performed with Mann–Whitney test. Patients with unknown aetiology were excluded from statistical analysis. a) White
blood cells; b) pentraxin 3; c) presepsin; d) C-reactive protein; e) procalcitonin; f ) calprotectin.
TABLE 2 Logistic regression analysis and diagnostic accuracy of biomarker levels at hospital
admission for prediction of bacterial aetiology in 267 hospitalised patients with
community-acquired pneumonia
Biomarker Univariate analysis Area under the curve
OR (95% CI) p-value AUC (95% CI) p-value
CRP 1.90 (1.16–3.12) 0.011 0.66 (0.56–0.75) 0.003
PCT 1.44 (1.15–1.81) 0.002 0.67 (0.58–0.77) 0.001
Calprotectin 2.15 (1.05–4.41) 0.036 0.63 (0.52–0.73) 0.022
CRP: C-reactive protein; PCT: procalcitonin.
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(table S2). In line with this finding, high admission levels of PCT, PTX3 and presepsin were all associated
with an adverse short-term outcome in univariate logistic regression analysis and in analyses adjusted for
the CURB-65 severity score (table 3).
However, admission levels of PCT (AUC 0.66, 95% CI 0.57–0.75; p=0.001), PTX3 (AUC 0.68, 95% CI
0.60–0.77; p<0.001) and presepsin (AUC 0.65, 95% CI 0.56–0.74; p=0.002) provided only moderate value
of discrimination between patients with an adverse and nonadverse short-term outcome (figure 3). The
optimal cut-off value for discriminating between patients with an adverse and nonadverse short-term
outcome for PCT was 0.91 ng·mL−1 (sensitivity 72%, specificity 58%), for PTX3 was 4.22 ng·mL−1
(sensitivity 83%, specificity 50%) and for presepsin was 64.5 pg·mL−1 (sensitivity 64%, specificity 61%).
Biomarker levels combined with the CURB-65 severity score in relation to short-term outcome
A CURB-65 severity score ⩾3 was significantly associated with an adverse short-term outcome (OR 3.83,
95% CI 2.00–7.32; p<0.001) and provided moderate value of discrimination (AUC 0.66, 95% CI 0.58–0.75;
p<0.001) for short-term outcome prediction (figure 3). The combination of a CURB-65 score ⩾3 with
admission levels of PCT (AUC 0.72, 95% CI 0.64–0.79; p<0.001), PTX3 (AUC 0.73, 95% CI 0.64–0.82;
p<0.001) and presepsin (AUC 0.73, 95% CI 0.65–0.81; p<0.001) improved the diagnostic accuracy for
TABLE 3 Logistic regression analysis of biomarker levels at hospital admission and
associations to adverse short-term outcome in 267 hospitalised patients with
community-acquired pneumonia
Biomarker Univariate analysis Multivariate analysis#
OR (95% CI) p-value OR (95% CI) p-value
PCT 1.40 (1.16–1.69) 0.001 1.29 (1.06–1.58) 0.012
PTX3 2.46 (1.49–4.06) <0.001 1.88 (1.11–3.19) 0.018
Presepsin 1.40 (1.12–1.74) 0.003 1.32 (1.04–1.67) 0.022
PCT: procalcitonin; PTX3: pentraxin 3. #: adjusted for the CURB-65 severity score (confusion, urea
>7 mmol·L−1, respiratory rate ⩾30 breaths·min−1, blood pressure <90 mmHg (systolic) or ⩽60 mmHg






































































FIGURE 3 Receiver operating characteristic curves for biomarkers and CURB-65 severity score (confusion,
urea >7 mmol·L−1, respiratory rate ⩾30 breaths·min−1, blood pressure <90 mmHg (systolic) or ⩽60 mmHg
(diastolic), age ⩾65 years) at hospital admission for prediction of an adverse short-term outcome.
a) Procalcitonin; b) pentraxin 3; c) presepsin. AUC: area under the curve.
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discriminating between patients with an adverse and nonadverse short-term outcome, although only
significantly for presepsin (p-value for difference: p=0.077, p=0.097 and p=0.042, respectively) (figure 3).
Biomarker levels at hospital admission in relation to long-term outcome
Of 257 short-term survivors of CAP, 67 (26%) died within 5 years post-discharge. Cumulative 5-year
survival rate was 74% (95% CI 68–79%). In univariate Cox regression analysis, increased admission levels
of PTX3 were associated with 5-year all-cause mortality (hazard ratio (HR) 1.63, 95% CI 1.13–2.35;
p=0.010). However, when adjusting for age and clinically relevant comorbid conditions (heart failure,
active malignant disease, chronic obstructive pulmonary disease and renal disease), PTX3 levels were no
longer significantly associated with 5-year all-cause mortality (HR 1.47, 95% CI 0.99–2.18; p=0.052).
Biomarker levels at 6-week follow-up in relation to long-term outcome
Increased levels of WBCs, CRP, PCT, calprotectin and PTX3 in samples obtained at the 6-week follow-up
were associated with 5-year all-cause mortality in univariate Cox regression analysis (table 4). In
multivariate Cox regression analysis with adjustment for age and clinically relevant comorbid conditions,
only calprotectin and WBCs remained significantly associated with 5-year all-cause mortality (table 4 and
figure 4).
Discussion
First, in this cohort of 267 hospitalised patients with CAP, calprotectin was an independent marker of
bacterial aetiology, and provided a diagnostic accuracy for discriminating bacterial from viral infections
comparable to the established inflammatory biomarkers CRP and PCT, thus suggesting it primarily reflects
bacterially mediated inflammation. Secondly, the novel inflammatory biomarkers PTX3 and presepsin
were, in addition to PCT, but not CRP, associated with an adverse short-term outcome in CAP, also after
adjustment for the CURB-65 severity score. Thirdly, admission levels of the biomarkers examined were not
useful for long-term outcome prediction but importantly, levels of calprotectin along with WBCs in the
convalescent phase of CAP, at the 6-week follow up, were independent predictors of 5-year all-cause
mortality.
A considerable overlap of CRP levels in bacterial, mixed viral–bacterial and viral CAP was found in the
present study, in line with observations from clinical practice and other similar studies [3, 7, 21].
Nevertheless, CRP was an independent marker of bacterial aetiology with a moderate discriminatory value,
and results for CRP were comparable to PCT. The calcitonin precursor PCT is believed to rise rapidly in
the systemic circulation, within 2–3 h, in response to infectious bacterial stimuli and may reach levels 100
000-fold above normal in sepsis, while viral stimuli do not induce the same PCT response [3, 7]. Thus, in
most analyses of PCT in lower respiratory tract infections such as CAP, this inflammatory marker has
offered a moderately good ability to differentiate bacterial from viral aetiology [22, 23], a finding which
also was confirmed in our study. However, our data suggest that PCT may not be superior to CRP for
discriminating between bacterial and viral aetiology in CAP.
Calprotectin is a complex of S100A8 and S100A9, two damage-associated molecular pattern molecules,
which are primarily released from activated or necrotic neutrophils, including via neutrophil extracellular
traps (NETs), although monocytes and macrophages also are cellular sources to circulating calprotectin
levels [24]. The calprotectin complex functions as an innate immune mediator in systemic infections like
pneumonia and sepsis, exerting its effects via activation of pattern recognition molecules, and by recruiting
TABLE 4 Cox regression analysis of biomarker levels at the 6-week follow-up and associations
to 5-year all-cause mortality in 267 hospitalised patients with community-acquired pneumonia
Biomarker Univariate analysis Multivariate analysis#
HR (95% CI) p-value HR (95% CI) p-value
WBCs 4.74 (1.89–11.87) 0.001 2.81 (1.06–7.44) 0.037
CRP 1.67 (1.34–2.08) <0.001 1.29 (0.99–1.67) 0.055
PCT 2.82 (1.71–4.63) 0.001 1.73 (0.97–3.09) 0.063
Calprotectin 2.56 (1.62–4.04) <0.001 2.18 (1.27–3.74) 0.005
PTX3 2.31 (1.49–3.59) <0.001 1.26 (0.83–1.92) 0.282
HR: hazard ratio; WBC: white blood cell; CRP: C-reactive protein; PCT: procalcitonin; PTX3: pentraxin 3.
#: adjusted for age, heart failure, active malignant disease, chronic obstructive pulmonary disease and
renal disease.
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neutrophils and other immune cells to the site of inflammation [25, 26]. Previously, elevated levels of
calprotectin have been reported in both serum and bronchoalveolar lavage fluid from patients with CAP
caused by S. pneumoniae [16]. In our study, calprotectin levels had a dynamic temporal profile and were
associated with bacterial aetiology, with highest levels in patients with mixed viral–bacterial aetiology.
Importantly, however, none of the examined biomarkers could reliably separate bacterial from viral
infections in CAP and determine if antibiotic treatment could be safely avoided.
The inflammatory markers PCT, PTX3 and presepsin were all associated with an adverse short-term
outcome, defined as ICU admission or 30-day mortality, and discriminated between adverse and
nonadverse short-term outcomes with moderate accuracy. By combining a CURB-65 severity score ⩾3
with biomarker levels, the prognostic accuracy improved significantly for presepsin only. In accordance
with our results, admission levels of PCT have, in multiple previous studies, been associated with
short-term mortality, mostly providing moderate to high prognostic value [4, 27]. Presepsin is an
inflammatory biomarker derived from the sCD14 protein [28]. Compared with PCT and other existing
biomarkers, presepsin levels are suggested to rise earlier in systemic infections and to be more infection
specific [12, 28]. In the few studies performed in CAP, presepsin has been found to be higher in patients
with a severe course, serving as an independent predictor of severe CAP and 28-day mortality [13, 29].
Our study supports the previous findings on presepsin as a potential novel biomarker predicting
short-term outcome. Similarly, PTX3, which, like CRP, is part of the pentraxin family of pattern
recognition molecules, predicted short-term outcome in our cohort. In contrast to CRP, PTX3 is produced
at the site of infection by numerous cell types, including neutrophils and monocytes, upon stimulation by
inflammatory signals (e.g. cytokines or microbial moieties) [30]. In sepsis, PTX3 is believed to act as an
acute-phase protein, reach peak levels within 6–8 h and be a predictor of short-term mortality [30, 31];
and in CAP, PTX3 has been reported to correlate with disease severity [17]. The results from our study
support the hypothesis that PTX3 may be a prognostic marker in CAP, showing, for the first time, an
association between plasma PTX3 levels and adverse short-term outcome in CAP.
It has become increasingly clear that CAP survivors have a higher risk of long-term mortality after
hospitalisation in comparison to the general population [32]. The reason for this higher risk of death
post-pneumonia is insufficiently understood, although it may in part be attributed to an increase in major
cardiovascular events [19, 33]. Previously, admission levels of cardiovascular disease (CVD)-associated
biomarkers (troponin T, N-terminal pro-B-type natriuretic peptide and trimethylamine-N-oxide), but not
typical inflammatory markers like WBCs, CRP and PCT, have been associated with poor long-term
prognosis in CAP [5, 34–36]. In comparison, elevated hospital discharge levels of interleukin-6, as an
indication of persisting inflammation, were found to be associated with 1-year mortality in the Genetic
and Inflammatory Markers of Sepsis study [37]. Admission levels of inflammatory biomarkers were not
independent predictors of long-term mortality in our cohort. However, in samples from the convalescent
phase ∼6 weeks after discharge, both calprotectin and WBC levels were associated with 5-year all-cause
mortality in analyses adjusted for age and relevant comorbidities.
The observation that calprotectin and WBCs, which correlated strongly with neutrophils and are the main
source of systemic calprotectin [24], both were predictors of long-term prognosis suggests an impact of
WBCs and neutrophil activity on the continued inflammatory process beyond the acute phase of CAP.
CVD is the most common cause of long-term mortality in CAP survivors [19, 38]. Based on the role of





































Time from discharge years
10 2 3
p<0.001
Q1 3.1–5.6 ×109 per L
Q2 5.6–6.7 ×109 per L
Q3 6.7–8.5 ×109 per L
Q4 8.5–14.9 ×109 per L
4 5
FIGURE 4 Kaplan–Meier plots of biomarkers at 6-week follow-up and associations with 5-year all-cause
mortality, stratified by quartiles of a) calprotectin (p<0.001 by the log-rank test) and b) white blood cell count
(p<0.001). Q: quartile.
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cells could contribute to poor long-term prognosis in the CAP population. However, this will have to be
further investigated in forthcoming studies. Nonetheless, our findings suggest that patients with persistent
elevation of calprotectin along with WBCs should be followed more carefully, especially for the
development of CVD.
Limitations and strengths
The measure short-term outcome was defined as a composite endpoint of ICU admission and 30-day
mortality, and a majority of patients were categorised with the softer ICU survivor outcome parameter,
which may have affected our results. Strengths of our study include the number of patients with an
established microbiological diagnosis (63%), the long follow-up period of 5 years and the coverage of data
on long-term mortality, as only one patient was lost to follow-up, resulting in 5-year all-cause mortality
data on 99.6% of the population.
Conclusion
Calprotectin may represent a new marker of both bacterial aetiology and 5-year all-cause mortality, while
PTX3 and presepsin are potential novel predictors of short-term outcome in CAP. The elevated
calprotectin and WBC levels in the convalescent phase may reflect unfavourable persistent inflammation
associated with the increased risk of long-term mortality.
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